INVESTMENT BANKING FIRM HAS STRONG BACKGROUND IN BIOTECHNOLOGY
SHANGHAI, China, Aug. 26 /PRNewswire-FirstCall/ -- Sinobiomed, Inc. ("Sinobiomed", or "the Company") (OTC Bulletin Board: SOBM) is pleased to announce that it has retained CB Capital Partners, Inc. as its financial advisor to evaluate strategic alternatives to maximize shareholder value.
"While we are extremely pleased with the results obtained from the work undertaken to date on our three marketed and seven pipeline drugs, four of which are moving towards commercial release, we feel this success is not yet represented in shareholder value," said Banjun Yang, Company President and CEO. "We have invested heavily in the respective successful development of our products; now we need assistance in developing our Company's share valuation."
These product developments include:
-- The patented recombinant malaria vaccine candidate (PfCP2.9), for which Sinobiomed is now in discussions to initiate Phase IIb clinical trials
-- The Phase IIb clinical trials of the Company's patented anti-bleeding agent, recombinant Batroxobin (rBAT). Should the product proceed to Phase III clinical trials, it is expected that international governments and organizations would show significant interest. The Company has already received indications of interest from global pharmaceutical companies for joint development, marketing and production.
-- Recent applications for a Chinese and an international patent for recombinant human kallikrein-1 (rhK1), and for a Chinese patent for an innovative recombinant multivalent tuberculosis vaccine.
-- Continuing penetration of Chinese market of Sinobiomed's commercialized products, which treat a wide range of diseases including hepatitis B and hepatitis C. China is home to nearly one third of the world's hepatitis carriers.
"Collectively, these developments have substantially increased the
value of Sinobiomed, which has seen a dra
|SOURCE Sinobiomed, Inc.|
Copyright©2008 PR Newswire.
All rights reserved